{"chebi_id":"4798","chebi_name":"entacapone","chebi_synonyms":["(2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide","Entacapone","(E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide","Comtess","Comtan","entacaponum","N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide","entacapona"],"diffprof_id_observed":["MTBLS2145_0001_00000029","MTBLS2406_0001_00000009","MTBLS5828_0002_00000001"],"diffprof_id_var_observed":["MTBLS2406_0001_00000009"],"inchikey":"JRURYQJSLYLRLN-BJMVGYQFSA-N","inn_name":"entacapone","iupac_name":"(2<i>E</i>)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-<em>N</em>,<em>N</em>-diethylprop-2-enamide","num_study_observed":3,"reactome_ids":["R-HSA-112311","R-HSA-112315","R-HSA-112316","R-HSA-1643685","R-HSA-379397","R-HSA-379401","R-HSA-5663205","R-HSA-9679191","R-HSA-9679506","R-HSA-9824446"],"reactome_names":["Neurotransmitter clearance","Transmission across Chemical Synapses","Neuronal System","Disease","Enzymatic degradation of dopamine by COMT","Dopamine clearance from the synaptic cleft","Infectious disease","Potential therapeutics for SARS","SARS-CoV Infections","Viral Infection Pathways"],"study_id_observed":["MTBLS2145","MTBLS2406","MTBLS5828"],"study_id_var_observed":["MTBLS2406"],"synonym_name":"<em>N</em>,<em>N</em>-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide"}